Acadia Healthcare Company, Inc. SEC filings document the company's behavioral healthcare operations, public-company governance and capital structure. Its disclosures describe subsidiaries that own, operate or manage acute inpatient psychiatric facilities, specialty treatment facilities, comprehensive treatment centers, residential treatment centers and outpatient behavioral healthcare facilities in the U.S. and Puerto Rico.
Acadia's filings include Form 8-K reports on operating and financial results, Regulation FD materials, executive and director changes, separation and compensation arrangements, and shareholder voting outcomes. Proxy materials cover board elections, executive compensation, incentive compensation plans and annual-meeting proposals, while registered-security disclosures identify ACHC common stock on the NASDAQ Global Select Market.
Acadia Healthcare Company, Inc. (ACHC) is the subject of a Schedule 13G in which Dimensional Fund Advisors reported 4,698,457 shares as beneficially owned, equal to 5.0% of the class, as of September 30, 2026. Dimensional reported sole voting power over 4,594,468 shares and sole dispositive power over 4,698,457 shares, with no shared voting or dispositive power. The shares are owned by the Funds described in the filing; Dimensional disclaims beneficial ownership. It states that, to its knowledge, no individual Fund has an interest exceeding 5% of the class.
Acadia Healthcare Company, Inc. (ACHC) said the U.S. District Court for the Middle District of Tennessee preliminarily approved a proposed settlement of shareholder derivative actions on September 1, 2026. The proposed terms call for Defendants’ Side A-DIC insurance carriers to pay Acadia $12,000,000 within 30 days from the later of entry of the preliminary approval order and Acadia’s delivery of complete payment instructions. Acadia must return the payment within 10 business days after notice if the settlement fails to become effective.
Acadia also agreed to pay $4,750,000 in attorneys’ fees and expenses, subject to court approval. The governance reforms address disclosure review, insider-trading and whistleblower policies, clawback rules, quality and compliance reporting, executive compensation review, and technology oversight. The company is to adopt, implement and maintain the reforms within 90 days after issuance of a final approval order, for at least four years from the later of settlement effectiveness or reform adoption. Final court approval of the settlement and fee amount remains pending.
Acadia Healthcare Company, Inc. received an amended Schedule 13G filing (Amendment No. 2) from Khrom Investments Fund, LP, Khrom Capital Management LLC, and Eric Khrom reporting their beneficial ownership of its common stock. As of June 30, 2026, these reporting persons may be deemed to beneficially own in the aggregate 653,914 Shares of Acadia common stock.
This aggregate position represents approximately 0.72% of Acadia’s outstanding Shares, based on 91,967,027 Shares outstanding as of April 28, 2026. Khrom Investments is the direct beneficial owner of 647,006 Shares, while Mr. Khrom directly owns 6,908 Shares. Khrom Capital’s reported ownership reflects its voting and dispositive power over the Shares held by Khrom Investments. The filing confirms the group owns 5 percent or less of the class and notes that dividends and sale proceeds for Shares in accounts managed by Khrom Capital may be delivered to those accounts.
Wellington Management Group LLP and related entities report beneficial ownership of Acadia Healthcare Company, Inc. common stock on a Schedule 13G/A. The filing states aggregate beneficial ownership of 6.15% of the common stock, held through investment advisory clients of various Wellington investment advisers.
The Wellington entities report no sole voting or dispositive power, but significant shared powers across affiliates. Wellington Management Group LLP, Wellington Group Holdings LLP and Wellington Investment Advisors Holdings LLP each report shared voting power over 5,117,100 shares and shared dispositive power over 5,726,246 shares. Wellington Management Company LLP reports shared voting power over 5,053,404 shares and shared dispositive power over 5,469,756 shares. The securities are owned of record by advisory clients, who are entitled to dividends and sale proceeds, and no individual client is known to hold more than five percent of the class.
FMR LLC filed an amended Schedule 13G reporting beneficial ownership of common stock of Acadia Healthcare Company, Inc. As of 06/30/2026, FMR LLC reported beneficial ownership of 5,015,726.57 shares, representing 5.5% of the outstanding common stock. FMR LLC reported sole voting power over 5,011,333 shares and sole dispositive power over 5,015,726.57 shares, with no shared voting or dispositive power.
Abigail P. Johnson is also listed as a reporting person, with sole dispositive power over 5,015,726.57 shares and no voting or shared powers. One or more other persons have rights to receive dividends or sale proceeds from these shares, but no such person holds more than five percent of Acadia’s common stock. The filing identifies relevant subsidiaries in an attached Exhibit 99 and is signed under powers of attorney by Stephanie J. Brown on behalf of FMR LLC and Abigail P. Johnson.
Acadia Healthcare Company, Inc. reported second quarter 2026 revenue of $865.8 million, approximately flat versus the prior year, while net income attributable to Acadia fell to $10.9 million from $30.1 million. Adjusted EBITDA declined to $149.2 million from $201.8 million and Adjusted EPS to $0.38 from $0.83, primarily reflecting a $39.3 million increase in PLGL costs, including a $28.6 million adjustment to PLGL reserves, and lower favorable impact from state supplemental payment programs.
Same-facility revenue was flat, with patient days up 0.8% and revenue per patient day down 0.8%, driven by the timing of supplemental payments; after normalizing for these items, management indicates same-facility revenue growth would have been 3.2%. Acute inpatient revenue was flat reported, but up 5.7% on a normalized basis, with Acute volumes up 5.5% due to expanded capacity. Specialty facility revenue decreased 8.4%, while residential treatment revenue increased 11.6%.
Acadia opened a 144-bed joint venture facility with Orlando Health and a 96-bed joint venture facility with Methodist Jennie Edmundson Hospital, plus two new CTC locations, adding 240 beds. As of June 30, 2026, it held $171.3 million in cash, had $669.8 million available under its $1.0 billion revolver, and reported a net leverage ratio of 4.1x Adjusted EBITDA. Full-year 2026 guidance was updated to revenue of $3.40–$3.45 billion, Adjusted EBITDA of $590–$615 million, Adjusted EPS of $1.45–$1.60, operating cash flow of $350–$400 million, and capital expenditures of $235–$255 million.
Acadia Healthcare Company, Inc. reported second-quarter 2026 revenue of 865,839 (in thousands), essentially flat versus the prior-year quarter, while net income attributable to the company declined to 10,928 (in thousands) and basic earnings per share were $0.12. For the first six months of 2026, revenue was 1,694,641 (in thousands) and net income attributable to the company was 15,033 (in thousands), down from 38,501 (in thousands) a year earlier.
Profitability was pressured by higher operating costs, a 7,364 (in thousands) non-cash property impairment charge, an unfavorable 28,600 (in thousands) actuarial adjustment to self-insured professional and general liability reserves, and 13,800 (in thousands) of Sandoval legal settlement expense not covered by excess insurance. Transaction, legal and other costs were 44,592 (in thousands) for the first half, including 19,893 (in thousands) related to government investigations and other litigation. The effective tax rate rose to 49.3% for the six-month period, driven by nondeductible legal settlements and higher valuation allowances.
Operating cash flow strengthened to 223,598 (in thousands) for the first six months of 2026, while capital expenditures fell to 115,117 (in thousands), supporting a cash balance of 171,290 (in thousands) at June 30, 2026. Long-term debt was 2,382,069 (in thousands), with 669.8 million of revolving credit availability, and the company remained in compliance with financial covenants. Acadia operated 279 facilities with approximately 12,600 beds across 40 states and Puerto Rico.
Acadia Healthcare Company, Inc. executive Brian Farley, EVP, CLAO and Secretary, reported a disposition of 1,770 shares of common stock on 2026-07-26 in a transaction coded F, covering exercise-price or tax-liability obligations at $34.51 per share. After this withholding event, he directly holds 135,982 shares.
BlackRock, Inc. filed an amended Schedule 13G reporting its beneficial ownership of common stock of Acadia Healthcare Company, Inc. BlackRock reported beneficial ownership of 13,831,925 shares, representing 15.0% of Acadia’s outstanding common stock.
BlackRock reported sole voting power over 13,688,826 shares and sole dispositive power over 13,831,925 shares, with no shared voting or dispositive power. The filing notes that one holder, iShares Core S&P Small-Cap ETF, has an interest in more than five percent of Acadia’s total outstanding common stock.
Acadia Healthcare Company, Inc. executive Brian Farley reported a routine tax-related share disposition. On this Form 4, Farley had 1,370 shares of Common Stock withheld at a price of $26.24 per share to cover tax obligations, a transaction classified as a tax-withholding disposition rather than an open-market sale. After this event, he continues to hold 137,752 shares of Acadia Healthcare Common Stock directly.